CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union Friday, [...]
Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple [...]
Teva announces COPAXONE® recognized as Brand of the Year by Pharmaceutical Executive Magazine JERUSALEM--(BUSINESS WIRE)--May 8, [...]
Leading Multiple Sclerosis Conference Offers Continuing Education Credit For Pharmacists The Cooperative Meeting of CMSC & ACTRIMS [...]
New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients Thursday, May 1, 2014 [...]
New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity Wednesday, April 30, 2014 7:30 [...]
A Farewell Tribute to Mike Robinson – President, Multiple Sclerosis Society of Zimbabwe POET AND SALUTATION DEDICATION: MR. [...]
Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s [...]
Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center Wednesday, April 30, 2014 [...]
Top Multiple Sclerosis Experts Headline Conference Focused on Comprehensive Approach to Care Leading Neurologists, Immunologists, and [...]